ArticleContemporary oncology (Poznan, Poland)2012

Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia.

Jan Styczyński et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.